Regeneron Pharmaceuticals plans to purchase 23andMe just two months after the genetics company filed for bankruptcy.

Regeneron will not acquire 23andMe's Lemonaid Health telehealth business. "We have deep experience with large-scale data management," Regeneron co-founder George Yancopoulos said in a statement.

Regeneron (NASDAQ: REGN) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous ...

Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered ...

“Regeneron is committed to advancing better ... sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a ...

Regeneron pledged to comply with 23andMe’s privacy policy, which allows customers to have their personal information deleted upon request. “We have deep experience with large-scale data management,” ...

Regeneron Pharmaceuticals ... measures the risks to and impacts on climate change through its enterprise risk management (ERM) program. Moreover, the health powerhouse has set environmental ...

Regeneron has agreed to buy 23andMe, the once buzzy genetic testing company, out of bankruptcy for $256 million under a court ...

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced st ...